Subscribe

Lynch Syndrome

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
By Wayne Kuznar
Lynch Syndrome
TON - September 2018, Vol 11, No 4
The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH. Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.